ArticleRSC advances2018
Shape-dependent adjuvanticity of nanoparticle-conjugated RNA adjuvants for intranasal inactivated influenza vaccines.
Article in RSC advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 33 citations in OpenAlex.
- Advancements in nanomaterial-based adjuvants for animal vaccines.Materials today. Bio · 2026Article
- Nanoparticles as Delivery Vehicles for Vaccines: The Use of Gold Nanoparticles.Current pharmaceutical biotechnology · 2026Review
- Nanoparticle‑based antiviral strategies to combat the influenza virus (Review).Biomedical reports · 2024Review
- A Novel Vision of Reinforcing Nanofibrous Masks with Metal Nanoparticles: Antiviral Mechanisms Investigation.Advanced fiber materials · 2023Review
- The Role of Mucoadhesion and Mucopenetration in the Immune Response Induced by Polymer-Based Mucosal Adjuvants.Polymers · 2023Review
- Immunomodulatory nanosystems: An emerging strategy to combat viral infections.Biomaterials and biosystems · 2023Review
- In vivo fate and intracellular trafficking of vaccine delivery systems.Advanced drug delivery reviews · 2022Review
- Innovative vaccine platforms against infectious diseases: Under the scope of the COVID-19 pandemic.International journal of pharmaceutics · 2021Review
- Design and Encapsulation of Immunomodulators onto Gold Nanoparticles in Cancer Immunotherapy.International journal of molecular sciences · 2021Review
- Molecular configuration-mediated thermo-responsiveness in oligo(ethylene glycol) derivatives attached on gold nanoparticles.Nanoscale advances · 2021Article
- Leveraging the modularity of biomaterial carriers to tune immune responses.Advanced functional materials · 2020Article
- Gold nanoparticles for preparation of antibodies and vaccines against infectious diseases.Expert review of vaccines · 2020Review
- Gold nanoparticle-adjuvanted S protein induces a strong antigen-specific IgG response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs.Microbiology and immunology · 2020Article
- Immunomodulatory Nanosystems.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2019Review
- Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy.Theranostics · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intranasal inactivated influenza vaccines can elicit mucosal immune responses that protect against virus infection. For the development of intranasal inactivated influenza vaccines, effective adjuvants inducing minimal adverse reactions are required. Generally, however, lower toxicity adjuvants have lower adjuvanticity. In this research, we fabricated nanoparticle-based adjuvants to enhance its adjuvanticity. Herein, we focused on low-molecular-weight polyinosinic-polycytidylic acid, referred to as uPIC(40:400), as a weak and less toxic RNA adjuvant. We conjugated uPIC(40:400) with different shaped gold nanoparticles (AuNPs) electrostatically. Conjugation with gold nanorods, but not spherical AuNPs, markedly enhanced the adjuvanticity of uPIC(40:400), leading to the suppression of viral infection in mice. Notably, conjugation with gold nanorods did not increase the inflammatory cytokine production in dendritic cells. These data indicated that gold nanorods can provide a good platform for enhancing the weak adjuvanticity of uPIC(40:400) while maintaining low inflammatory cytokine production toward the development of intranasal inactivated influenza vaccines.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.